RESUMO
Research on patient-centered care supports use of patient/consumer self-report measures in monitoring health outcomes. This study examined the incremental value of self-report mental health measures relative to a clinician-rated measure in predicting functional outcomes among mental health service recipients. Participants (n = 446) completed the Behavior and Symptom Identification Scale, the Brief Symptom Inventory, and the Veterans/Rand Short Form-36 at enrollment in the study (T1) and 3 months later (T2). Global Assessment of Functioning (GAF) ratings, mental health service utilization, and psychiatric diagnoses were obtained from administrative data files. Controlling for demographic and clinical variables, results indicated that improvement based on the self-report measures significantly predicted one or more functional outcomes (i.e., decreased likelihood of post-enrollment psychiatric hospitalization and increased likelihood of paid employment), above and beyond the predictive value of the GAF. Inclusion of self-report measures may be a useful addition to performance measurement efforts.
Assuntos
Transtornos Mentais/diagnóstico , Serviços de Saúde Mental/normas , Avaliação de Resultados em Cuidados de Saúde , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Veteranos/psicologia , Adolescente , Adulto , Idoso , Feminino , Seguimentos , Hospitais Psiquiátricos , Humanos , Masculino , Massachusetts , Transtornos Mentais/classificação , Transtornos Mentais/psicologia , Saúde Mental , Serviços de Saúde Mental/estatística & dados numéricos , Pessoa de Meia-Idade , Observação , Assistência Centrada no Paciente , Pacientes/estatística & dados numéricos , Estudos Prospectivos , Escalas de Graduação Psiquiátrica , Autorrelato , Transtornos Relacionados ao Uso de Substâncias/classificação , Inquéritos e Questionários , Estados Unidos , United States Department of Veterans Affairs , Adulto JovemRESUMO
In this commentary, we review recent research suggesting that (a) second-generation antipsychotics (SGAs) may be no more effective than first-generation antipsychotics (FGAs), (b) the reduced risk of EPS and tardive dyskinesia with SGAs is more weakly supported by the research literature than has been appreciated, and (c) benefits may be offset by greater metabolic risks of some SGAs and their substantially greater cost. Bearing in mind, as well, that risperidone, currently the least expensive SGA, will soon be available as an even less expensive generic drug, we propose a new algorithm for maintenance antipsychotic therapy. We further outline a cautious implementation procedure that relies on standardized documentation and feedback, without a restrictive formulary that would limit physician choice. The algorithm outlined here and the process for its implementation are intended as a stimulus for discussion of potential policy responses, not as a finalized proposition.
